A computational model demonstrates complex, dose-dependent interactions between beta-adrenergic and muscarinic cholinergic stimulation on action potential duration in atrial myocytes.
Answers are grounded in this paper and cite their sources.
Model predictions of dose-dependent Iso/ACh effects on APD should not guide clinical decisions; leaves open validation in intact hearts and humans.
A model of beta-adrenergic and muscarinic cholinergic effects on the bullfrog atrial myocyte has been developed to simulate the dose-dependent effects of isoprenaline (Iso) on the action potential duration (APD); i.e., low doses of Iso lengthen the APD, whereas high doses shorten the APD. In this model, the reduction in APD is the result of 1) calcium-dependent inactivation of calcium current (ICa) resulting from the enhancement of ICa by Iso and 2) an enhancement of potassium current (IK) due to both an Iso-induced increase in the rate of activation of IK and an increase in peak action potential height. The effect of acetylcholine (ACh) is simulated by a reduction in the Iso-induced increase in ICa and IK through a reduction in relative adenosine 3',5'-cyclic monophosphate concentration ([cAMP]), as well as activation of the ACh-sensitive potassium current. At low [Iso] levels in the presence of a high [ACh], the muscarinic cholinergic effects dominate the beta-adrenergic change. However, for a large [Iso] and a small [ACh], this pattern of changes in transmembrane currents is different; in this case the model predicts that ACh can actually increase APD.
No takes yet. Share an insight, caveat, or question.
Shumaker et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: